Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Oct 22;63(11):e01024-19.
doi: 10.1128/AAC.01024-19. Print 2019 Nov.

Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion

Urania Rappo #  1 , Michael W Dunne #  2 , Sailaja Puttagunta  2 , James S Baldassarre  2 , Shengfang Su  2 , Daksha Desai-Krieger  2 , Megumi Inoue  3
Affiliations
Clinical Trial

Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion

Urania Rappo et al. Antimicrob Agents Chemother. .

Abstract

Dalbavancin is a lipoglycopeptide antibiotic with a prolonged half-life. A phase 1 study assessed dalbavancin levels in epithelial lining fluid (ELF) in 35 healthy adults using ELF bronchial microsampling up to 168 h after administration of 1,500 mg dalbavancin. The penetration of dalbavancin into ELF was 36%. ELF levels of dalbavancin exceeded the MIC90s of Streptococcus pneumoniae and Staphylococcus aureus for ≥7 days.

Keywords: dalbavancin; lung epithelial lining fluid; pharmacodynamics; pharmacokinetics; pneumonia.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Individual dalbavancin concentration-time profile in ELF (blue) and unbound plasma (red) (semilog scale). ELF samples were collected at 4, 8, 12, 24, 72, 120, and 168 h; and plasma PK samples were collected at 0.5, 1, 2, 4, 8, 12, 24, 72, 120, and 168 h.
See this image and copyright information in PMC

References

    1. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. 2014. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 370:2169–2179. doi:10.1056/NEJMoa1310480. - DOI - PubMed
    1. Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J. 2016. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis 62:545–551. doi:10.1093/cid/civ982. - DOI - PMC - PubMed
    1. Andes D, Craig WA. 2007. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 51:1633–1642. doi:10.1128/AAC.01264-06. - DOI - PMC - PubMed
    1. Lepak A, Marchillo K, VanHecker J, Andes D. 2015. Impact of glycopeptide resistance in Staphylococcus aureus on the dalbavancin in vivo pharmacodynamic target. Antimicrob Agents Chemother 59:7833–7836. doi:10.1128/AAC.01717-15. - DOI - PMC - PubMed
    1. Dunne M, Koeth LM, Windau AR. 2012. The effect of lung surfactant on the in vitro activity of dalbavancin against Staphylococcus aureus and Streptococcus pneumoniae, poster 1622. ID Week, San Diego, CA.

Publication types

MeSH terms